Trials / Completed
CompletedNCT01007539
Efficacy and Safety of CDP-choline in Patients With Methamphetamine Dependence
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Seoul National University Hospital · Academic / Other
- Sex
- All
- Age
- 19 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to determine if cytidine 5'diphosphocholine (CDP-choline, a naturally occurring chemical in your body) has efficacy in reducing the methamphetamine craving of the subjects with methamphetamine dependence craving and helping them maintain the abstinence. In addition, investigators will measure the brain N-acetyl aspartate (a biologic marker for neuronal viability) level of participants to determine if brain deficits induced by methamphetamine may recover by taking CDP-choline.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | CDP-choline | The subjects will be given 1g citicoline twice daily for a total of 8 weeks. |
| DIETARY_SUPPLEMENT | Placebo (fructose) | The Subjects will be given 2 tablets of placebo twice daily for 8 weeks. They will be taking the same quantity as the CDP-choline group. |
Timeline
- Start date
- 2009-11-01
- Primary completion
- 2012-01-01
- Completion
- 2012-01-01
- First posted
- 2009-11-04
- Last updated
- 2012-08-31
Locations
2 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01007539. Inclusion in this directory is not an endorsement.